NeoGenomics Reports Second Quarter 2026 Results
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer